Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Pipeline perspectives - Peripheral artery disease Poor disease awareness hinders new agents (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 19/12/2007
- Report Title: Pipeline perspectives - Peripheral artery disease Poor disease awareness hinders new agents
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 90
Introduction
Peripheral artery disease, sometimes also referred to as peripheral vascular disease, is atherosclerosis in peripheral regions, which can lead to loss of blood flow to the limbs, and can result in loss of life, limb amputation and cardiovascular events. The current pharmacological treatment options are limited, and there are large unmet needs associated with the disease.
Scope
Evaluate therapies under development for peripheral artery disease (PAD) A detailed clinical and commercial assessment of all key emerging therapies Epidemiological based sales forecasts for key late-stage developmental heart failure agents in the seven major markets to 2016
Highlights
PAD is severely undertreated and underdiagnosed. Despite the high prevalence (23.4 million subjects by 2016) and grave consequences, such as cardiovascular events, amputations and death, PAD is not considered as "fascinating" as coronary artery disease and the lack of PAD awareness even among physicians is staggering.
Drug therapy plays a limited role in the management of PAD, due to the restricted treatment options. For intermittent claudication (IC) patients the mainstay of pharmacological treatment is prevention of CV events with antiplatelets and statins. Cilostazol (Pletal), an antiplatelet, is recommended as first-line therapy for claudication
The new agents in development for PAD are primarily as secondary indications. This is due to the issues new agents will face reaching the underdiagnosed, undertreated patient population. Overall, there are very few clinical trials to develop PAD agents, and the trials are very much underpowered.
Reasons to Purchase
Understand patient segmentation relevant to pipeline products and analyze competitive environment at time of product launch Justify go/no-go decisions on basis of potential return on investment Utilize product profiles to aid pricing and reimbursement decisions
Scope
Highlights
Reasons to Purchase
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
